These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2929999)

  • 1. Pharmacokinetics of intravenous dantrolene in children.
    Lerman J; McLeod ME; Strong HA
    Anesthesiology; 1989 Apr; 70(4):625-9. PubMed ID: 2929999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of dantrolene following oral administration in malignant hyperthermia-susceptible patients.
    Allen GC; Cattran CB; Peterson RG; Lalande M
    Anesthesiology; 1988 Dec; 69(6):900-4. PubMed ID: 3057938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenously administered dantrolene and its 5-hydroxy metabolite in dogs.
    Wuis EW; Vree TB; Van Der Kleijn E
    Int J Clin Pharmacol Res; 1990; 10(4):203-10. PubMed ID: 2079379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of dantrolene sodium in horses.
    Court MH; Engelking LR; Dodman NH; Anwer MS; Seeler DC; Clark M
    J Vet Pharmacol Ther; 1987 Sep; 10(3):218-26. PubMed ID: 3656508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiopulmonary bypass interference with dantrolene prophylaxis of malignant hyperthermia.
    Larach DR; High KM; Larach MG; Hensley FA; Martin DE; Williams DR
    J Cardiothorac Anesth; 1987 Oct; 1(5):448-53. PubMed ID: 2979114
    [No Abstract]   [Full Text] [Related]  

  • 6. Simultaneous determination of dantrolene and its metabolites, 5-hydroxydantrolene and nitro-reduced acetylated dantrolene (F 490), in plasma and urine of man and dog by high-performance liquid chromatography.
    Wuis EW; Grutters AC; Vree TB; van der Kleyn E
    J Chromatogr; 1982 Sep; 231(2):401-9. PubMed ID: 7130316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work?
    Podranski T; Bouillon T; Schumacher PM; Taguchi A; Sessler DI; Kurz A
    Anesth Analg; 2005 Dec; 101(6):1695-1699. PubMed ID: 16301243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of dantrolene in horses.
    DiMaio Knych HK; Arthur RM; Taylor A; Moeller BC; Stanley SD
    J Vet Pharmacol Ther; 2011 Jun; 34(3):238-46. PubMed ID: 21492188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant hyperthermia susceptibility--successful management with a "stressfree" technique.
    Jantzen JP; Erdmann K; Kleemann PP
    Acta Anaesthesiol Belg; 1987; 38(1):107-13. PubMed ID: 3591264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of dantrolene in an adult patient undergoing cardiopulmonary bypass.
    Comunale ME; DiNardo JA; Schwartz MJ
    J Cardiothorac Vasc Anesth; 1991 Apr; 5(2):153-5. PubMed ID: 1863728
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of oral dantrolene in the dog.
    Haraschak JL; Langston VC; Wang R; Riggs C; Fellman C; Ross MK; Bulla C; Lunsford K; Mackin A; Archer T
    J Vet Pharmacol Ther; 2014 Jun; 37(3):286-94. PubMed ID: 24219828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiological effects of intravenous dantrolene on canine heart.
    Roewer N; Kuck KH; Kochs E; Schulte am Esch J
    Eur J Anaesthesiol; 1987 Sep; 4(5):357-67. PubMed ID: 3428281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effects of intravenously administered dantrolene.
    Wedel DJ; Quinlan JG; Iaizzo PA
    Mayo Clin Proc; 1995 Mar; 70(3):241-6. PubMed ID: 7861811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of dantrolene and its metabolite, 5-hydroxydantrolene, in human plasma by high-performance liquid chromatography.
    Katogi Y; Tamaki N; Adachi M; Terao J; Mitomi M
    J Chromatogr; 1982 Mar; 228():404-8. PubMed ID: 7076770
    [No Abstract]   [Full Text] [Related]  

  • 15. [Caesarean section in a patient with past history of fulminant malignant hyperthermia].
    Goto S; Ogata K; Fujie T; Fujigaki T; Nakamura H; Yukinari T; Shibata O
    Masui; 1993 Feb; 42(2):271-5. PubMed ID: 8437362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant hyperthermia after oral and intravenous pretreatment with dantrolene in a patient susceptible to malignant hyperthermia.
    Ruhland G; Hinkle AJ
    Anesthesiology; 1984 Feb; 60(2):159-60. PubMed ID: 6696240
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients.
    Inotsume N; Higashi A; Matsukane I; Chikazawa S; Nakano M; Matsuda I
    Pediatr Pharmacol (New York); 1986; 5(4):253-9. PubMed ID: 3737270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs.
    Schütte JK; Becker S; Burmester S; Starosse A; Lenz D; Kröner L; Wappler F; Gerbershagen MU
    Eur J Anaesthesiol; 2011 Apr; 28(4):256-64. PubMed ID: 21513076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dantrolene in pregnancy: lack of adverse effects on the fetus and newborn infant.
    Shime J; Gare D; Andrews J; Britt B
    Am J Obstet Gynecol; 1988 Oct; 159(4):831-4. PubMed ID: 3177531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. General anesthesia in a malignant hyperthermia susceptible patient.
    Jones JE; Dierdorf SF; Clapp DW
    J Oral Med; 1987; 42(1):22-4, 66. PubMed ID: 2950215
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.